Follow
richard schlenk
richard schlenk
Unknown affiliation
Verified email at nct-heidelberg.de
Title
Cited by
Cited by
Year
Genomic classification and prognosis in acute myeloid leukemia
E Papaemmanuil, M Gerstung, L Bullinger, VI Gaidzik, P Paschka, ...
New England Journal of Medicine 374 (23), 2209-2221, 2016
38572016
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
RM Stone, SJ Mandrekar, BL Sanford, K Laumann, S Geyer, ...
New England Journal of Medicine 377 (5), 454-464, 2017
20972017
Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
RF Schlenk, K Döhner, J Krauter, S Fröhling, A Corbacioglu, L Bullinger, ...
New England Journal of Medicine 358 (18), 1909-1918, 2008
20672008
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia
F Lo-Coco, G Avvisati, M Vignetti, C Thiede, SM Orlando, S Iacobelli, ...
New England Journal of Medicine 369 (2), 111-121, 2013
1633*2013
Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia
L Bullinger, K Döhner, E Bair, S Fröhling, RF Schlenk, R Tibshirani, ...
New England Journal of Medicine 350 (16), 1605-1616, 2004
12422004
Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene …
K Döhner, RF Schlenk, M Habdank, C Scholl, FG Rücker, ...
Blood 106 (12), 3740-3746, 2005
11102005
Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials
J Koreth, R Schlenk, KJ Kopecky, S Honda, J Sierra, BJ Djulbegovic, ...
Jama 301 (22), 2349-2361, 2009
10862009
Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML …
S Fröhling, RF Schlenk, J Breitruck, A Benner, S Kreitmeier, K Tobis, ...
Blood, The Journal of the American Society of Hematology 100 (13), 4372-4380, 2002
10862002
IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 …
P Paschka, RF Schlenk, VI Gaidzik, M Habdank, J Kronke, L Bullinger, ...
J Clin Oncol 28 (22), 3636-3643, 2010
9952010
p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias
H Dohner, K Fischer, M Bentz, K Hansen, A Benner, G Cabot, D Diehl, ...
9821995
Targeting FLT3 mutations in AML: review of current knowledge and evidence
N Daver, RF Schlenk, NH Russell, MJ Levis
Leukemia 33 (2), 299-312, 2019
8492019
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
FG Rücker, RF Schlenk, L Bullinger, S Kayser, V Teleanu, H Kett, ...
Blood, The Journal of the American Society of Hematology 119 (9), 2114-2121, 2012
6962012
CEBPA Mutations in Younger Adults With Acute Myeloid Leukemia and Normal Cytogenetics: Prognostic Relevance and Analysis of Cooperating Mutations
S Fröhling, RF Schlenk, I Stolze, J Bihlmayr, A Benner, S Kreitmeier, ...
Journal of Clinical Oncology 22 (4), 624-633, 2004
6302004
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
S Kayser, K Doehner, J Krauter, CH Koehne, HA Horst, G Held, ...
Blood, The Journal of the American Society of Hematology 117 (7), 2137-2145, 2011
5092011
Monitoring of Minimal Residual Disease in NPM1-Mutated Acute Myeloid Leukemia: A Study From the German-Austrian Acute Myeloid Leukemia Study Group
J Krönke, RF Schlenk, KO Jensen, F Tschürtz, A Corbacioglu, VI Gaidzik, ...
Journal of Clinical Oncology 29 (19), 2709-2716, 2011
4792011
The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach
JJ Cornelissen, A Gratwohl, RF Schlenk, J Sierra, M Bornhaeuser, ...
Nature reviews Clinical oncology 9 (10), 579-590, 2012
4662012
Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation
RF Schlenk, S Kayser, L Bullinger, G Kobbe, J Casper, M Ringhoffer, ...
Blood, The Journal of the American Society of Hematology 124 (23), 3441-3449, 2014
4392014
Individual patient data–based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia …
RF Schlenk, A Benner, J Krauter, T Buchner, C Sauerland, G Ehninger, ...
Journal of Clinical Oncology 22 (18), 3741-3750, 2004
4392004
Prognostic impact, concurrent genetic mutations, and gene expression features of AML with CEBPA mutations in a cohort of 1182 cytogenetically normal AML patients: further …
E Taskesen, L Bullinger, A Corbacioglu, MA Sanders, CAJ Erpelinck, ...
Blood, The Journal of the American Society of Hematology 117 (8), 2469-2475, 2011
4372011
Prognostic Significance of Partial Tandem Duplications of the MLL Gene in Adult Patients 16 to 60 Years Old With Acute Myeloid Leukemia and Normal …
K Döhner, K Tobis, R Ulrich, S Fröhling, A Benner, RF Schlenk, ...
Journal of Clinical Oncology 20 (15), 3254-3261, 2002
4062002
The system can't perform the operation now. Try again later.
Articles 1–20